Roche Holding Stock Forecast for 2023 - 2025 - 2030
Updated on 04/01/2023
Roche Holding Stock Forecast and Price Target
Roche Holding's stock is projected to advance by 24.32% from the previous closing price if it reaches the average target of CHF365.00 by the year's end, as nine reputable analysts recently projected. This potential upside is calculated on a high-end estimate of CHF450.00 and a low-end estimate of CHF265.00. If you're looking for information on Roche Holding stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.
24.32% Upside
Roche Holding Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Roche Holding's Price has seen a drop from CHF320.95 to CHF315.38 – a 1.74% decrease. According to 0 major analysts, Roche Holding's Fair Value will fall by 0.45% in the next year, reaching CHF313.97. Professionals believe that By 2030, Roche Holding's Fair Value will fall to CHF313.79– a 0.50% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$343.42 | Buy/Sell | $333.19 | 16.48% |
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$159.36 | Buy/Sell | $162.24 | 3.54% |
| AVGO Stock Forecast | Broadcom | Outperform |
9
|
$641.35 | Buy/Sell | $656.43 | 2.75% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
8
|
£11.25k | Buy/Sell | £153.20 | -98.61% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$101.26 | Buy/Sell | $121.44 | 23.44% |
Roche Holding Revenue Forecast for 2023 - 2025 - 2030
Roche Holding's Revenue has increased by 3.29% In the last two years, going from CHF63.75B to CHF65.85B. According to 0 major analysts, Roche Holding's Revenue will fall by 3.69% in the next year, reaching CHF63.42B. Professionals believe that By 2030, Roche Holding's Revenue will fall to CHF63.48B– a 3.60% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DHR Stock Forecast | Danaher Corp | Outperform |
10
|
$252.04 | Buy/Sell | $304.24 | 20.81% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$241.75 | Buy/Sell | $268.00 | 14.99% |
| GE Stock Forecast | General Electric | Outperform |
9
|
$95.60 | Buy/Sell | $86.47 | -9.00% |
.jpg)
Roche Holding Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Roche Holding's Dividend per Share has grown, increasing from CHF9.00 to CHF9.30 – a growth of 3.33%. In the next year, 0 analysts estimate that Roche Holding's Dividend per Share will decrease by 1.80%, reaching CHF9.13. According to professional forecasts, in 2030, Roche Holding's Dividend per Share will decrease by 1.72%, reaching CHF9.14.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$247.48 | Buy/Sell | $268.00 | 11.12% |
| MMM Stock Forecast | 3M | Hold |
16
|
$105.08 | Buy/Sell | $147.79 | 13.72% |
| GSK Stock Forecast | GSK | Hold |
16
|
£1.43k | Buy/Sell | £16.95 | -98.87% |
Roche Holding Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Roche Holding's Free Cash Flow has decreased from CHF18.88B to CHF17.45B – a 7.59% drop. In the following year, 0 experts forecast that Roche Holding's Free Cash Flow will decrease by 0.69%, to CHF17.33B. In 2030, professionals predict that Roche Holding's Free Cash Flow will decrease by 1.00%, to CHF17.27B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BSX Stock Forecast | Boston Scientific | Outperform |
15
|
$50.03 | Buy/Sell | $52.51 | -0.06% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.07k | Buy/Sell | ¥0.00 | 35.30% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
58.72€ | Buy/Sell | 74.54€ | 28.58% |
Roche Holding Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Roche Holding's Net Income has grown by 3.21%, from CHF13.50B to CHF13.93B. According to 0 analysts, Roche Holding's Net Income will fall by 0.11% in the next year, reaching CHF13.91B. Professionals believe that By 2030, Roche Holding's Net Income will fall to CHF13.92B – a 0.04% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 6501 Stock Forecast | Hitachi | Buy |
18
|
¥6.56k | Buy/Sell | ¥0.00 | 29.65% |
| DXCM Stock Forecast | DexCom | Outperform |
16
|
$116.17 | Buy/Sell | $129.69 | 8.03% |
| A Stock Forecast | Agilent Technologies | Outperform |
17
|
$138.34 | Buy/Sell | $162.50 | 20.36% |
Roche Holding EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Roche Holding's EBITDA has decreased by 2.83%, going from CHF24.97B to CHF24.27B. For next year, analysts predict EBITDA of CHF24.39B, which would mean an increase of 0.49%. Over the next nine years, experts predict that Roche Holding's EBITDA will grow at a rate of 0.41%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CTVA Stock Forecast | Corteva Inc | Outperform |
12
|
$60.29 | Buy/Sell | $73.12 | 21.08% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.31k | Buy/Sell | ¥0.00 | 36.03% |
| DD Stock Forecast | DuPont de Nemours | Outperform |
17
|
$71.78 | Buy/Sell | $80.32 | 11.45% |
Roche Holding EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Roche Holding's EBIT has decreased from CHF21.03B to CHF20.19B – a 4.02% drop. For next year, analysts predict EBIT of CHF20.32B, which would mean an increase of 0.64%. Over the next nine years, experts predict that Roche Holding's EBIT will grow at a rate of 0.54%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALC Stock Forecast | Alcon | Outperform |
15
|
CHF66.18 | Buy/Sell | CHF0.00 | 30.51% |
| ILMN Stock Forecast | Illumina Inc | Outperform |
16
|
$232.55 | Buy/Sell | $254.08 | 7.29% |
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr3.00k | Buy/Sell | kr2.84k | -8.24% |
Roche Holding EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Roche Holding's EPS has seen a drop from CHF20.16 to CHF19.81 – a 1.74% decrease. According to 0 major analysts, Roche Holding's EPS will fall by 0.45% in the next year, reaching CHF19.72. Professionals believe that By 2030, Roche Holding's EPS will fall to CHF19.71– a 0.50% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PODD Stock Forecast | Insulet | Outperform |
15
|
$318.96 | Buy/Sell | $302.13 | 0.33% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$72.28 | Buy/Sell | $88.18 | 18.98% |
| 4523 Stock Forecast | Eisai | Hold |
18
|
¥8.15k | Buy/Sell | ¥0.00 | -18.99% |
.jpg)